Quetzal Therapeutics

Quetzal Therapeutics is a Cambridge-based biotechnology company focused on developing next-generation precision medicines for cancer by targeting the DNA Damage Response (DDR). Founded in 2023 by industry veterans Professor Steve Jackson and Niall Martin—the team behind successful DDR pioneers KuDOS Pharmaceuticals and Artios Pharma—the company leverages deep expertise in genome stability to identify and drug novel vulnerabilities in cancer cells. Quetzal aims to expand the therapeutic potential of DDR beyond current PARP inhibitors, focusing on innovative small molecule approaches to overcome resistance and improve patient outcomes. The company is currently in the early stages of building its discovery pipeline, utilizing a proprietary platform to target specific proteins involved in DNA repair and replication stress.